There is no official definition of a microdose of tirzepatide. No regulator or approved label defines the term, so any number you see quoted is one prescriber's judgment, not a standard. Microdosed tirzepatide at Telos Rx is prescribed only after review by a licensed provider.
That is unsatisfying if you came for a figure, so this page explains what the approved label does specify, why microdose has no position inside it, and what really decides the amount.
Why No Official Microdose Exists
A drug gets a defined dose because a manufacturer studied it and the FDA reviewed and approved specific amounts for specific uses. That process produces the prescribing information, which is what makes a number authoritative.
Microdosing never went through that process. No company has submitted a microdose product for approval, no approved microdose label exists, and no professional body has published a threshold that separates a microdose from a regular dose.
So when an article says a microdose of tirzepatide is a particular amount, it is not citing a standard. It is reporting a practice, and practices vary where standards do not.
What the Approved Label Actually Specifies
Tirzepatide is a dual GIP and GLP-1 receptor agonist made by Eli Lilly. The same molecule is approved under two brand names: Mounjaro for type 2 diabetes, and Zepbound for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity.
In adults, both carry the same escalation schedule in their FDA prescribing information, for Zepbound and for Mounjaro: 2.5 mg once weekly for four weeks, then increases in 2.5 mg increments after at least four weeks on the current dose, up to a maximum of 15 mg once weekly in adults.
| Approved labelled dosing | Microdosing | |
|---|---|---|
| Defined by | FDA-reviewed prescribing information for Mounjaro and Zepbound | Nothing. No regulator or standards body |
| Starting amount | Label specifies 2.5 mg once weekly for four weeks | No specified amount anywhere |
| How it changes | Label specifies 2.5 mg increments, no sooner than every four weeks | Decided by the prescriber for that individual |
| Ceiling | Label maximum is 15 mg once weekly in adults | None published |
| How it is supplied | FDA-approved brand products in fixed-dose presentations | Compounded preparations, which are not FDA-approved |
The left column describes the approved label. It is not guidance for you, and not a chart to follow.
The Detail Most Articles Miss
Here is the part that settles the question. The Zepbound label states that the 2.5 mg starting dose is for treatment initiation and is not approved as a maintenance dosage. The approved maintenance options sit above it.
The smallest amount in the entire approved schedule is already considered too low to stay on. A microdose, by definition, sits below even that.
So microdosing is not a lower rung on the approved ladder. It is off the ladder. That is why no official figure exists to give you, and why anyone who hands you one with confidence is overstating what is known.
Why Every Source Quotes a Different Number
With no definition to anchor to, each clinic and article fills the gap with its own convention. One prescriber's idea of a microdose can differ substantially from another's, and both can describe themselves accurately, because there is nothing to be inaccurate against.
The numbers also drift by source and over time, because they reflect prescribing habits, not published thresholds. Our companion explainer on what GLP-1 microdosing is and how it works covers the concept across the drug class.
Treat any specific figure you read as an example of what someone did, never as a target for you. An article cannot know your health history, medications or tolerance, and those are the inputs that decide the answer.
No article can tell you what your amount should be, because that is a clinical decision about you specifically. A written intake reviewed by a licensed provider is where the question actually gets answered.
See microdosed tirzepatide at Telos RxWhy Microdosing Involves Compounded Vials
There is a physical reason microdosing is not simply a brand option. Mounjaro and Zepbound are supplied in fixed-dose presentations, including single-dose pens and multi-dose pens that deliver preset weekly amounts, built to give the labelled dose.
You cannot dial an arbitrary amount out of a delivery system designed around fixed increments. That is the structural constraint, and it is the reason microdosing in practice happens with compounded tirzepatide supplied in a vial, where a prescriber can specify an amount outside the brand increments.
Compounded tirzepatide is not FDA-approved. As the FDA explains, compounded drugs do not go through the agency's review of safety, effectiveness and quality. They are prepared by licensed US compounding pharmacies against a prescription for an individual patient. The dependency is covered in why microdosing tirzepatide requires compounding.
What Actually Determines the Amount
Since no article can supply the number, it is worth knowing what does. A prescriber works from your health history, current medications, any contraindications, what you have tolerated before, why microdosing is being considered at all, and how you respond over time.
Tirzepatide carries a boxed warning for thyroid C-cell tumours observed in rodents, and both brands are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Candidacy is assessed before any amount is discussed.
Everything is subject to medical approval by a licensed provider, and approval is not guaranteed. What changes at lower amounts is covered in microdosing GLP-1 side effects.
What the Evidence Does and Does Not Support
The pivotal trials studied the labelled dose range. SURMOUNT-1, published in the New England Journal of Medicine, and the SURPASS programme in type 2 diabetes both evaluated the amounts that went on to be approved.
No large randomised trial has established the efficacy of microdosed tirzepatide. The rationale rests on pharmacological reasoning and clinical experience, not phase 3 data, and it would be dishonest to present it as anything more.
Microdosing should also not be called more effective, safer or superior to standard dosing. It is a provider-directed approach chosen for particular reasons in particular people, compared side by side in microdose vs standard tirzepatide.
If You Came Looking for a Chart
Wanting a chart is reasonable, and there is a legitimate place to send that: the approved label, laid out in the tirzepatide dosage guide. If your question is really about converting an amount into a volume, tirzepatide dosing in mL explains why no universal calculator can exist.
What no honest page can give you is a microdose chart, because there is nothing to chart. Publishing one would mean inventing a standard.
How the Telos Rx Process Works
Telos Rx is an online-first, asynchronous telehealth service. You complete a written intake covering health history and current medications, and a licensed provider reviews it in writing, often within hours, with no scheduled appointment.
Microdosed tirzepatide at Telos Rx is a weekly subcutaneous protocol with provider-personalised dosing, available in all 50 states through licensed US compounding pharmacies, with formulations that can vary by state. As of publication, pricing starts as low as $116 per month, down from $279, with free 48-hour shipping if approved, FSA and HSA accepted, and cancel anytime.
Keep Reading
- Microdose vs Standard Tirzepatide: How They Differ
- Microdosing Tirzepatide vs Semaglutide: Compared
- Microdosing GLP-1 Side Effects: What Changes
- Why Microdosing Tirzepatide Requires Compounding
- Telos Rx vs Noom Microdose: GLP-1 Programs Compared
- Microdosing Tirzepatide Schedule: Benefits and Side Effects
Frequently Asked Questions
What is considered a microdose of tirzepatide?
There is no agreed answer, because no regulator, manufacturer or approved label defines the term. In practice, prescribers use it to describe an amount below the standard labelled titration, chosen for an individual after review. That is why numbers quoted online vary so widely, and why none of them carries any official standing.
Is there an official microdose amount on the tirzepatide label?
No. The approved prescribing information for Mounjaro and Zepbound describes a starting dose, fixed escalation increments and a weekly maximum. It contains no microdose category and no sub-starting amount. Anything smaller than the labelled starting dose sits outside the approved framework entirely, which is precisely why no official figure exists to quote.
Why does every website quote a different microdose number?
Because each one is describing a prescriber preference rather than a standard. With no definition to anchor to, one clinic's idea of a microdose can differ substantially from another's, and both can describe themselves accurately. Treat any specific figure you read as an example of what someone did, not as a benchmark for you.
Is microdosing tirzepatide FDA-approved?
No. Microdosing is not an FDA-approved concept, and there is no approved microdose product or label. Compounded tirzepatide is also not FDA-approved. Microdosing a compounded preparation therefore sits outside the approved framework on both counts, which is why it requires a prescription and ongoing oversight from a licensed provider.
Can you microdose brand Mounjaro or Zepbound pens?
The brand products are supplied in fixed-dose presentations, including single-dose pens and multi-dose pens that deliver preset weekly amounts. Those devices are designed to give the labelled dose, not an amount you or a prescriber selects. That structural limit is the main reason microdosing in practice involves compounded tirzepatide supplied in a vial.
Does a smaller dose mean fewer side effects?
Not automatically, and nobody should promise it. The approved label uses gradual escalation specifically to reduce the risk of gastrointestinal reactions, so dose and tolerability are related. Tirzepatide still carries a boxed warning for thyroid C-cell tumours seen in rodents and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
If the honest answer left you wanting a real one, that is the right instinct: the number is a clinical decision, not an editorial one. Start at the microdosed tirzepatide page, then complete the written intake for your evaluation at start an online visit. A licensed provider reviews every request, and approval is not guaranteed.